Table.
Baseline characteristics of patients in TOPCAT by categories of H2FPEF-score (n=362)
| H2FPEF score | H2FPEF score | H2FPEF score | ||
|---|---|---|---|---|
| ≤3 | >3 to <6 | ≥6 | ||
| n=100 (28%) | n=130 (36%) | n=132 (36%) | P | |
| Age (years) | 69.9 ± 11.2 | 70.7 ± 9.4 | 74.7 ± 8.7 | <0.001 |
| Male | 34 (34.0%) | 61 (46.9%) | 68 (51.5%) | 0.009 |
| Black race | 19 (19.0%) | 33 (25.4%) | 15 (11.4%) | 0.09 |
| Region | 0.017 | |||
| Russia and Georgia | 20 (20.0%) | 17 (13.1%) | 12 (9.1 %) | |
| The Americas | 80 (80.0%) | 113 (86.9%) | 120 (90.9%) | |
| Eligibility Criteria | 0.64 | |||
| Prior HF Hospitalization in 12mo | 61 (61.0%) | 82 (63.1%) | 77 (58.3%) | |
| Elevated NP in 60 days | 39 (39.0%) | 48 (36.9%) | 65 (41.7%) | |
| New York Heart Association Class III or IV | 41 (41.4%) | 56 (43.4%) | 63 (47.7%) | 0.33 |
| Hypertension | 94 (94.0%) | 118 (90.8%) | 122 (92.4%) | 0.71 |
| Diabetes Mellitus | 35 (35.0%) | 59 (45.4%) | 59 (44.7%) | 0.16 |
| Previous Myocardial Infarction | 22 (22.0%) | 29 (22.3%) | 31 (23.5%) | 0.78 |
| Previous Cerebrovascular Accident | 12 (12.0%) | 9 (6.9 %) | 17 (12.9%) | 0.72 |
| Peripheral Artery Disease | 10 (10.0%) | 19 (14.6%) | 9 (6.8 %) | 0.35 |
| History of Atrial Fibrillation | 1 (1.0 %) | 44 (33.8%) | 132 (100.0%) | <0.001 |
| Body Mass Index (kg/m2) | 29.5 ± 8.2 | 34.0 ± 8.2 | 34.4 ± 7.4 | <0.001 |
| Waist Circumference (cm) | 98.7 ± 16.1 | 107.0 ± 16.0 | 110.9 ± 16.1 | <0.001 |
| Systolic Blood Pressure (mmHg) | 128.5 ± 16.6 | 125.4 ± 16.3 | 123.7 ± 15.0 | 0.025 |
| eGFR (ml/min/1.73 m2) | 65.8 ± 21.3 | 64.4 ± 20.9 | 59.7 ± 18.1 | 0.018 |
| N-terminal pro-B-type NP (ng/L) | 791 [437 , 2054] | 1068 [475 , 1615] | 1354 [751 , 2023] | 0.32 |
| B-type NP (ng/L) | 234 [155 , 698 ] | 208 [130 , 375 ] | 329 [165 , 568 ] | 0.21 |
| Baseline Medication Use | ||||
| β-blocker | 76 (76.0%) | 106 (81.5%) | 102 (77.3%) | 0.89 |
| Calcium Channel Blocker | 38 (38.0%) | 63 (48.5%) | 55 (41.7%) | 0.67 |
| Diuretic | 81 (81.0%) | 113 (86.9%) | 123 (93.2%) | 0.005 |
| ACEi/ARB | 72 (72.0%) | 107 (82.3%) | 109 (82.6%) | 0.06 |
| Aspirin | 72 (72.0%) | 82 (63.1%) | 70 (53.0%) | 0.003 |
| Statin | 66 (66.0%) | 86 (66.2%) | 89 (67.4%) | 0.81 |
| Baseline Echocardiography | ||||
| LV ejection fraction (%) | 60.6 ± 8.1 | 60.1 ± 7.4 | 58.8 ± 7.9 | 0.07 |
| LV mass index (g/ m2) | 104.8 ± 32.1 | 109.4 ± 26.7 | 109.5 ± 33.2 | 0.28 |
| LV end diastolic volume index (ml/m2) | 49.8 ± 15.9 | 49.3 ± 15.1 | 43.8 ± 12.9 | 0.002 |
| LA volume index (ml/m2) | 29.1 ± 10.9 | 31.4 ± 9.6 | 36.5 ± 18.7 | <0.001 |
| E/e’ lateral ratio | 12.4 ± 5.4 | 12.4 ± 6.6 | 13.1 ± 7.0 | 0.41 |
| Pulmonary Artery Systolic Pressure (mmHg) | 35.7 ± 10.8 | 35.0 ± 11.0 | 40.1 ± 11.4 | 0.002 |
Data reported as n (%), mean ± standard deviation or median (quartile 1 to quartile 3)
Abbreviations: ACEi/ARB = angiotensin-converting enzyme inhibitor / angiotensin II receptor blocker; eGFR = estimated glomerular filtration rate; HF=heart failure; NP = natriuretic peptide; LV, left ventricular; LA, left atrial